Monday, November 14, 1994
Broad-brush approach to connective tissue disorders
Connective tissue disorders encompass a wide variety of conditions, from rheumatoid
arthritis to cirrhosis to scleroderma. While they have been treated as individual
diseases, advances in understanding of the underlying biology are making clear the
connections between them and the logic of attempting to treat them as a group.
One of the first biotechnology companies to do so is Connective Therapeutics Inc., a
Palo Alto, Calif., startup that is focused on the interaction of the immune system with
connective tissues. The company's goal is to make use of the body's natural physiology to
restore the normal functioning of the proteins and cellular interactions that are
disregulated in chronic connective tissue diseases.